CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MOSTERT, J. W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by MOSTERT, J. W.

Canadian Journal of Anesthesia, Vol 10, 241-243, Copyright © 1963 by Canadian Anesthesiologists' Society

L'Hexafluorenium, antagoniste de l'hexabiscarbacholine dans l'anesthesie chez l'humain

J. W. MOSTERT M.B., CH.B., F.F.A.R.C.S. (ENG.), D.A.1

1 Hôpital Général, Université de Witwatersrand, Johannesburg, Afrique du Sud

The place of hexamethylene-l, 6-biscarbaminoylcholine (Imbretil) as a relaxant in anaesthesia is controversial, particularly after reports1,2 appeared which left doubt as to its reversibility in as consistent and conclusive a manner as is the case with tubocurarine. This preliminary report describes the effectiveness of hexafluorenium (Mylaxen) in blocking the depressant action of hexacarbacholine on the respiration in 18 patients, and in antagonizing the effect of hexabiscarbacholine at varying times up to approximately 15 minutes after administration of hexabiscarbacholine in a further 7 patients. When this antagonism became attenuated neostigmine reversibility became apparent. This antagonism, and similarly a tachycardia which was constantly observed after hexafluorenium administration, cannot be explained by the current theories on the mode of action of these drugs.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1963 by the Canadian Anesthesiologists' Society.